Positive FDA Guidance for Phase III received for Revacept
Silver Springs, Maryland, and Martinsried, Germany, 07. August 2024: The U.S Food and Drug Association (FDA) has reviewed the preclinical and clinical development program for Revacept / PR-15 in a Type C meeting. Further on, the future clinical development program until market approval was presented and discussed with the FDA.